Therapeutic Opportunities for Targeting microRNAs in Cancer
DOI:
https://doi.org/10.13052/mct2052-8426.812Keywords:
Antisense oligonucleotides, biomarkers, chemotherapeutics, locked nucleic acids, metastamiR, metastasis, microRNA, oncomiRAbstract
MicroRNAs (miRNAs) are small noncoding RNAs that can function as either powerful tumor promoters or suppressors in numerous types of cancer. The ability of miRs to target multiple genes and biological signaling pathways has created intense interest in their potential clinical utility as predictive and diagnostic biomarkers, and as innovative therapeutic agents. Recently, accumulating preclinical studies have illustrated the feasibility of slowing tumor progression by either overexpressing tumor suppressive miRNAs, or by neutralizing the activities of oncogenic miRNAs in cell- and animal-based models of cancer. Here we highlight prominent miRNAs that may represent potential therapeutic targets in human malignancies, as well as review current technologies available for inactivating or restoring miRNA activity in clinical settings.
References
Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9–29.
Li GW, Xie XS: Central dogma at the single-molecule level in living cells. Nature 2011, 475:308–315.
Esteller M: Non-coding RNAs in human disease. Nat Rev Genet 2011, 12:861–874.
Ling H, Fabbri M, Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013, 12:847–865.
Garzon R, Marcucci G, Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010, 9:775–
Ambros V: The functions of animal microRNAs. Nature 2004, 431:350–355.
Ventura A, Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136:586–591.
Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA: MicroRNAs– the micro steering wheel of tumour metastases. Nat Rev Cancer 2009,
:293–302.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human
microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004, 101:2999–
Mendell JT, Olson EN: MicroRNAs in stress signaling and human disease. Cell 2012, 148:1172–1187.
Leung AK, Sharp PA: MicroRNA functions in stress responses. Mol Cell 2010, 40:205–215.
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R,
King BD, Kauppinen S, Levin AA, Hodges MR: Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, 368:1685–1694.
Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat
Cell Biol 2009, 11:228–234.
Trabucchi M, Briata P, Garcia-Mayoral M, Haase AD, Filipowicz W, Ramos A, Gherzi R, Rosenfeld MG: The RNA-binding protein KSRP
promotes the biogenesis of a subset of microRNAs. Nature 2009, 459:1010–1014.
Yi R, Qin Y, Macara IG, Cullen BR: Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003,
:3011–3016.
Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD: A cellular function for the RNA-interference enzyme
Dicer in the maturation of the let-7 small temporal RNA. Science 2001, 293:834–838.
Khvorova A, Reynolds A, Jayasena SD: Functional siRNAs and miRNAs exhibit strand bias. Cell 2003, 115:209–216.
Blahna MT, Hata A: Regulation of miRNA biogenesis as an integrated component of growth factor signaling. Curr Opin Cell Biol 2013,
:233–240.
Sun X, Jiao X, Pestell TG, Fan C, Qin S, Mirabelli E, Ren H, Pestell RG: MicroRNAs and cancer stem cells: the sword and the shield.
Oncogene 2013, doi:10.1038/onc.2013.492. [Epub ahead of print].
Davis BN, Hilyard AC, Lagna G, Hata A: SMAD proteins control DROSHAmediated microRNA maturation. Nature 2008, 454:56–61.
Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A: SMAD proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell 2010, 39:373–384.
Piriyapongsa J, Jordan IK, Conley AB, Ronan T, Smalheiser NR: Tran- scription factor binding sites are highly enriched within microRNA
precursor sequences. Biol Direct 2011, 6:61.
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K: Modulation of microRNA processing by p53. Nature
, 460:529–533.
Zhang X, Wan G, Berger FG, He X, Lu X: The ATM kinase induces microRNA biogenesis in the DNA damage response. Mol Cell 2011,
:371–383.
Briata P, Lin WJ, Giovarelli M, Pasero M, Chou CF, Trabucchi M, Rosenfeld MG, Chen CY, Gherzi R: PI3K/AKT signaling determines
a dynamic switch between distinct KSRP functions favoring skeletal myogenesis. Cell Death Differ 2012, 19:478–487.
Paroo Z, Ye X, Chen S, Liu Q: Phosphorylation of the human micro-RNAgenerating complex mediates MAPK/Erk signaling. Cell 2009,
:112–122.
Roush S, Slack FJ: The let-7 family of microRNAs. Trends Cell Biol 2008, 18:505–516.
Yamagata K, Fujiyama S, Ito S, Ueda T, Murata T, Naitou M, Takeyama K, Minami Y, O’Malley BW, Kato S: Maturation of
microRNA is hormonally regulated by a nuclear receptor. Mol Cell 2009, 36:340–347.
Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, Du Y, Wang Y, Chang WC, Chen CH, Hsu JL, Wu Y, Lam YC, James
BP, Liu X, Liu CG, Patel DJ, Hung MC: EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2.
Nature 2013, 497:383–387.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57–70.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646–674.
Chou J, Shahi P, Werb Z: microRNA-mediated regulation of the tumor microenvironment. Cell Cycle 2013, 12(20):3262–3271.
doi:10.4161/cc.26087. Epub 2013 Aug 26.
Yates LA, Norbury CJ, Gilbert RJ: The long and short of microRNA. Cell 2013, 153:516–519.
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ,
Hammond SM: A microRNA polycistron as a potential human onco- gene. Nature 2005, 435:828–833.
Tanzer A, Stadler PF: Molecular evolution of a microRNA cluster. J Mol Biol 2004, 339:327–335.
Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, Seto M: Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004, 64:3087–3095.
Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K: Lymphoproliferative disease
and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008, 9:405–414.
Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C, Jensen K, Cobb BS, Merkenschlager M, Rajewsky
N, Rajewsky K: Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008, 132:860–874.
Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch
R, Sharp PA, Jacks T: Targeted deletion reveals essential and overlap-ping functions of the miR-17 through 92 family of miRNA clusters.
Cell 2008, 132:875–886.
Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazzini L, Volinia
S, Alder H, Ruco LP, Baldassarre G, Croce CM, Vecchione A: E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and
apoptosis in gastric cancer. Cancer Cell 2008, 13:272–286.
Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson AL, Linsley PS, Cleary
MA: MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008, 28:2167–2174.
Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A:
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006, 38:1060–1065.
Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, Ford HL: The miR-106b-25 cluster targets Smad7, activates TGF-beta
signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 2012, 31:5162–
Chan JA, Krichevsky AM, Kosik KS: MicroRNA-21 is an antiapop-totic factor in human glioblastoma cells. Cancer Res 2005, 65:6029–
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza
G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer
gene targets. Proc Natl Acad Sci USA 2006, 103:2257–2261.
Jazbutyte V, Thum T: MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets 2010, 11:926–935.
Pan X, Wang ZX, Wang R: MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2010, 10:1224–1232.
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H: High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-b1. Breast Cancer Res Treat 2009, 117:131–140.
Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, Liao Y, Du J: High expression of miR-21 and miR-155 predicts recurrence and
unfavourable survival in non-small cell lung cancer. Eur J Cancer 2013, 49:604–615.
Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE: Accumulation of miR-155 and BIC RNA in human B
cell lymphomas. Proc Natl Acad Sci USA 2005, 102:3627–3632.
Tam W, Hughes SH, Hayward WS, Besmer P: Avian bic, a gene isolated from a common retroviral site in avian leukosis virus-induced
lymphomas that encodes a noncoding RNA, cooperates with c-myc in lymphomagenesis and erythroleukemogenesis. J Virol 2002, 76:4275–4286.
Tili E, Croce CM, Michaille JJ: miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 2009, 28:264–284.
Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ: MicroRNA-155 is regulated by the transforming growth factor b/Smad
pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008, 28:6773–6784.
Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF, Wang ED: MicroRNA-155 functions as an OncomiR in breast cancer by
targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010, 70:3119–3127.
Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ: MicroRNA-155 regulates cell survival, growth, and chemosen-
sitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010, 285:17869–17879.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M,
Bullrich F, Croce CM: Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic
leukemia. Proc Natl Acad Sci USA 2002, 99:15524–15529.
Dong JT, Boyd JC, Frierson HF Jr: Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate 2001,
:166–171.
Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S,
Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce CM: miR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad
Sci USA 2008, 105:5166–5171.
Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D’Urso L, Pagliuca A, Biffoni M, Labbaye C, Bartucci M, Muto
G, Peschle C, De Maria R: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med
, 14:1271–1277.
Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G: The 21-nucleotide let-7 RNA
regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403:901–906.
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64:3753–3756.
Shi XB, Tepper CG, deVere White RW: Cancerous miRNAs and their regulation. Cell Cycle 2008, 7:1529–1538.
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E: Let-7 regulates self renewal and tumorigenicity
of breast cancer cells. Cell 2007, 131:1109–1123.
Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ: MicroRNAs as potential agents to alter resis-
tance to cytotoxic anticancer therapy. Cancer Res 2007, 67:11111–11116.
Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ: MicroRNA let-7a down-regulates
MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007, 67:9762–9770.
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the
let-7 microRNA family. Cell 2005, 120:635–647.
Lee YS, Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007, 21:1025–1030.
Ugalde AP, Ramsay AJ, de la Rosa J, Varela I, Marino G, Cadinanos J, Lu J, Freije JM, Lopez-Otin C: Aging and chronic DNA damage
response activate a regulatory pathway involving miR-29 and p53. EMBO J 2011, 30:2219–2232.
Zhang Y, Wu L, Wang Y, Zhang M, Li L, Zhu D, Li X, Gu H, Zhang CY, Zen K: Protective role of estrogen-induced miRNA-29 expression
in carbon tetrachloride-induced mouse liver injury. J Biol Chem 2012, 287:14851–14862.
Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce
CM: MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114:5331–5341.
Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W,
Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G: MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and
indirectly DNMT1. Blood 2009, 113:6411–6418.
Kapinas K, Kessler CB, Delany AM: miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by
canonical Wnt signaling. J Cell Biochem 2009, 108:216–224.
Mott JL, Kobayashi S, Bronk SF, Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007, 26:6133–6140.
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM: Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis
of hepatocellular carcinoma. Hepatology 2010, 51:836–845.
Filkowski JN, Ilnytskyy Y, Tamminga J, Koturbash I, Golubov A, Bagnyukova T, Pogribny IP, Kovalchuk O: Hypomethylation and
genome instability in the germline of exposed parents and their progeny is associated with altered miRNA expression. Carcinogenesis
, 31:1110–1115.
Luna C, Li G, Qiu J, Epstein DL, Gonzalez P: Cross-talk between miR-29 and transforming growth factor-βs in trabecular meshwork
cells. Invest Ophthalmol Vis Sci 2011, 52:3567–3572.
Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M: Transcriptional activation of
miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007, 26:731–743.
He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW,
Cleary MA, Hannon GJ: A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130–1134.
Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR,
Fearon ER: p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007, 17:1298–1307.
Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T, Ito M: Effects of miR-34a on cell growth and chemore-
sistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008, 377:114–119.
Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P, Bellan C, van Rijk A, Nyagol J, Byakika B, Lazzi S, Tosi P, van Krieken H,
Leoncini L: MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA dereg-
ulation. J Pathol 2008, 216:440–450.
Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J, Khan J: The MYCN oncogene is a direct
target of miR-34a. Oncogene 2008, 27:5204–5213.
Yamakuchi M, Ferlito M, Lowenstein CJ: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008, 105:13421–
Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H: Inactivation of
miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591–2600.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10–29.
Vanharanta S, Massague J: Origins of metastatic traits. Cancer Cell 2013, 24:410–421.
Taylor MA, Parvani JG, Schiemann WP: The pathophysiology of epithelialmesenchymal transition induced by transforming growth
factor-β in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 2010, 15:169–190.
Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, Parenti AR, Daidone
MG, Bicciato S, Piccolo S: A MicroRNA targeting dicer for metastasis control. Cell 2010, 141:1195–1207.
Hurst DR, Edmonds MD, Welch DR: Metastamir: the field of metas-tasisregulatory microRNA is spreading. Cancer Res 2009, 69:7495–
White NM, Fatoohi E, Metias M, Jung K, Stephan C, Yousef GM: Metastamirs: a stepping stone towards improved cancer management.
Nat Rev Clin Oncol 2011, 8:75–84.
Korpal M, Lee ES, Hu G, Kang Y: The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct
targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283:14910–14914.
Park SM, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the
E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894–907.
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and
miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593–601.
Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM:
Contextual extracellular cues promote tumor cell EMT and metas-tasis by regulating miR-200 family expression. Genes Dev 2009,
:2140–2151.
Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celia-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia
BA, Ragoussis J, Amadori D, Harris AL, Kang Y: Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes
metastatic colonization. Nat Med 2011, 17:1101–1108.
Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F,Speleman F, Vandesompele J, Weinberg RA: miR-9, a MYC/MYCN- activated microRNA, regulates E-cadherin and cancer metastasis. Nat
Cell Biol 2010, 12:247–256.
Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC, Ma L: LIFR is a breast
cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med 2012, 18:1511–1517.
Zheng L, Qi T, Yang D, Qi M, Li D, Xiang X, Huang K, Tong Q: microRNA-9 suppresses the proliferation, invasion and metastasis of
gastric cancer cells through targeting cyclin D1 and Ets1. PLoS One 2013, 8:e55719.
Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA: A pleiotropically act-
ing microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009, 137:1032–1046.
Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA: Con-comitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev 2009, 23:2592–2597.
Sossey-Alaoui K, Downs-Kelly E, Das M, Izem L, Tubbs R, Plow EF: WAVE3, an actin remodeling protein, is regulated by the metas-
tasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int J Cancer 2011, 129:1331–1343.
Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metas-tasis initiated by microRNA-10b in breast cancer. Nature 2007,
:682–688.
Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J: miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009, 4:e7181.
Ma L: Role of miR-10b in breast cancer metastasis. Breast Cancer Res 2010, 12:210.
Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H, Liu Z: MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal
cancer cell lines. J Biol Chem 2010, 285:7986–7994.
Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW, Weinberg RA: Therapeutic silencing of
miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010, 28:341–347.
Seoudi AM, Lashine YA, Abdelaziz AI: MicroRNA-181a-a tale of discrepancies. Expert Rev Mol Med 2012, 14:e5.
Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP: TGF-β upregulates miR-181a expression to promote
breast cancer metastasis. J Clin Invest 2013, 123:150–163.
Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, Rankin-Gee EK, Wang SE: Transforming growth factor-b regulates the sphere-
initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011, 30:1470–1480.
Parikh A, Lee C, Peronne J, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D,
D’Incalci M, Rahaman J, Kalir T, Redline RW, Brown BD, Narla G, Di Feo A: microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun 2014, 5:2977.
Weiler J, Hunziker J, Hall J: Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene
Ther 2006, 13:496–502.
Cummins LL, Owens SR, Risen LM, Lesnik EA, Freier SM, McGee D, Guinosso CJ, Cook PD: Characterization of fully 2′-modified olig-
oribonucleotide hetero and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res 1995, 23:2019–2024.
Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M: Silencing of microRNAs in vivo with ‘antagomirs’.
Nature 2005, 438:685–689.
Manoharan M: 2′-carbohydrate modifications in antisense oligonu-cleotide therapy: importance of conformation, configuration and con-jugation. Biochim Biophys Acta 1999, 1489:117–130.
Davis S, Lollo B, Freier S, Esau C: Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006, 34:2294–2304.
Vester B, Wengel J: LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 2004, 43:13233–
Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjarn M, Hansen HF, Berger U, Gullans S, Kearney
P, Sarnow P, Straarup EM, Kauppinen S: LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896–899.
Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H: Therapeutic silencing of
microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198–201.
Ebert MS, Neilson JR, Sharp PA: MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007,
:721–726.
Choi WY, Giraldez AJ, Schier AF: Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 2007, 318:271–274.
Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ: Systemic delivery of tumor sup-
pressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011, 19:1116–1122.
Aagaard L, Rossi JJ: RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007, 59:75–86.
Michelfelder S, Trepel M: Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet 2009, 67:29–60.
Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark
KR, Mendell JR, Mendell JT: Therapeutic microRNA delivery sup-presses tumorigenesis in a murine liver cancer model. Cell 2009, 137:
–1017.
Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A: Small-molecule inhibitors of microRNA miR-21 function. Angew
Chem Int Ed Engl 2008, 47:7482–7484.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet- Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T,
Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature 2005, 435:834–838.
Liu A, Tetzlaff MT, Vanbelle P, Elder D, Feldman M, Tobias JW, Sepulveda AR, Xu X: MicroRNA expression profiling outperforms
mRNA expression profiling in formalin-fixed paraffin-embedded tis-sues. Int J Clin Exp Pathol 2009, 2:519–527.
Weiland M, Gao XH, Zhou L, Mi QS: Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases.
RNA Biol 2012, 9:850–859.
